KOSPIBiotech & Pharma001360

Samsung Pharmaceutical

₩1,222▼ 1.29%2026-11-18 close
Market Cap
₩115.1B
Turnover
₩100M
Volume
110K
Shares out.
94.2M
PER
—
PBR
1.8×
EPS
-₩1,219
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Samsung Pharmaceutical: Losses Narrowing, Revenue Recovery Still Pending

Samsung Pharmaceutical narrowed its operating loss to KRW 2.8 billion in Q3 2026, but sales remain below the year-earlier quarter and the net loss attributable to controlling shareholders totals KRW 114.8 billion over the last four quarters.

  1. 1

    Q3 2026 operating loss narrowed to KRW 2.8 billion from a year earlier, while sales of KRW 10.2 billion fell 14.9% year on year.

  2. 2

    Net income attributable to controlling shareholders turned positive at KRW 11.5 billion in 2025, yet operating losses have persisted for four consecutive years, reaching KRW 18.1 billion in 2025.

  3. 3

    The cost of sales ratio climbed from 55.36% in 2024 to 69.66% in 2025, raising cost pressure.

  4. 4

    GV1001, a progressive supranuclear palsy treatment, was filed for conditional approval in January 2026 and is under review by the MFDS, alongside other pipeline programs such as Alzheimer's Phase 3.

  5. 5

    PER is not calculated because the last four quarters show net losses, and PBR sits above 1 times.

02

Business structure

Samsung Pharmaceutical was founded in 1929 and listed on the KOSPI in 1975 as a drug manufacturer and distributor. As of year-end 2025, prescription drugs accounted for 79.82% of sales, general drugs and quasi-drugs 13.12%, other 4.03%, and health functional foods 3.03%.

Prescription products are sold through a contract sales organization (CSO) model, while general drugs reach pharmacies and convenience stores through a separate OTC distribution affiliate. Eighteen prescription products are sold under a contract with a partner company.

A consolidated subsidiary makes and sells health functional foods; it generates some revenue but remains in net loss. In December 2025 the company entered a license-in agreement covering domestic rights to GV1001, a PSP treatment, and in January 2026 it applied for conditional domestic approval.

Its largest shareholder licensed pipelines covering pancreatic cancer, Alzheimer's disease and PSP. R&D spending was 7.51% of sales in 2025 on a standalone basis. The cost of sales ratio rose to 69.66% in 2025 from 55.36% in 2024. The business therefore combines product sales with license-based drug development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩12B-₩3.9B−32.1%
2025Q4₩11.8B-₩5.4B−45.8%
2026Q1₩9B-₩1.9B−21.0%
2026Q2₩9.9B-₩5.1B−51.8%
2026Q3₩10.2B-₩2.8B−27.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩51.8B-₩14B-₩25.1B−26.9%−24.5%14.9%
2023₩52B-₩18B-₩24.8B−34.7%−32.0%20.5%
2024₩44.3B-₩14.8B-₩14.1B−33.5%−13.3%21.3%
2025₩46.1B-₩18.1B₩11.5B−39.2%9.5%38.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed annual basis, sales were KRW 51.8 billion in 2022, KRW 52 billion in 2023, KRW 44.3 billion in 2024 and KRW 46.1 billion in 2025. 2023 was the largest year and 2024 the smallest in the 2022 to 2025 period, and 2025 sales rose 4.0% year on year.

Operating losses were KRW 14 billion in 2022, KRW 18 billion in 2023, KRW 14.8 billion in 2024 and KRW 18.1 billion in 2025, a run of four consecutive loss years from 2022 to 2025. Operating margins were -26.9%, -34.7%, -33.5% and -39.2% over the same years, so the loss widened again in 2025 even as sales grew.

On costs, the cost of sales ratio jumped from 55.36% in 2024 to 69.66% in 2025, and R&D spending and one-off expenses were cited as factors weighing on profitability.

Net income attributable to controlling shareholders was KRW 11.5 billion in 2025, a turn to profit from a KRW 14.1 billion loss in 2024, and total net income including non-controlling interests was also KRW 11.5 billion.

Because the operating loss of KRW 18.1 billion coexisted with a profit, the non-operating items should be checked in the notes to the 2025 annual report. Total equity at end-2025 was KRW 121 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 46.4 billion.

The debt-to-equity ratio rose from 14.9% in 2022 to 38.3% in 2025. Operating cash flow was negative in every year, at KRW -1.91 billion in 2022, KRW -27.7 billion in 2023, KRW -17.3 billion in 2024 and KRW -10.1 billion in 2025.

Quarterly sales fell from KRW 12 billion in Q3 2025 to a low of KRW 9.02 billion in Q1 2026, then rose to KRW 9.9 billion in Q2 and KRW 10.2 billion in Q3 2026, two consecutive quarters of growth.

The Q3 2026 operating loss of KRW 2.8 billion narrowed from KRW 3.85 billion a year earlier and from KRW 5.13 billion in Q2 2026. Net income attributable to controlling shareholders swung from a KRW 8.77 billion profit in Q1 2026 to a KRW 56.6 billion loss in Q2 and a KRW 7.77 billion loss in Q3.

The four quarters from Q4 2025 to Q3 2026 total a net loss attributable to controlling shareholders of KRW 114.8 billion, with the KRW 59.1 billion loss in Q4 2025 the largest single-quarter loss.

According to press reports, sales for January to September 2026 were KRW 29.1 billion, down from KRW 34.3 billion a year earlier, and cumulative net income swung from a KRW 70.6 billion profit to a KRW 55.6 billion net loss.

05

Industry analysis

The domestic pharmaceutical and biotech sector shows a sharp split in earnings. In the first-half 2026 analysis, profits concentrated in large biotech companies and high-margin firms.

Large biotech companies led first-half growth, while biopharmaceuticals, contract development and manufacturing (CDMO), and aesthetics and medical devices were strong. In the second half, new contract wins and plant utilization were cited as key variables for large biotech companies.

Domestic drugmakers are pursuing new drug development under drug price regulation. Samsung Pharmaceutical's structure differs from this trend, since CSO-based prescription sales and general drug distribution form the core and the biotech segment remains in clinical and approval stages.

Its revenue scale and profit structure differ greatly from large CDMO and biosimilar companies, which makes direct comparison difficult.

Within the sector, the company's position leans toward managing margins in a sales-centered model, and the rise in cost of sales to 69.66% in 2025 makes margin management a stated challenge. Whether sector strength reaches this company's sales will show up in the pace of quarterly sales recovery.

06

Outlook

The company's growth axis is the GV1001 pipeline. GV1001, a treatment for progressive supranuclear palsy, was filed for conditional domestic approval with the MFDS in January 2026 and is under review. The company has also previously submitted a domestic Phase 3 trial plan.

As an Alzheimer's disease treatment, GV1001 is in a domestic Phase 3 trial, and the PSP program is preparing for a Phase 2b/3 trial. A license agreement with its largest shareholder also secured a pancreatic cancer pipeline.

On the financing side, the company issued a 32nd series of unsecured private convertible bonds in August 2025, so the funding structure should be tracked in upcoming regular reports. Cumulative sales for January to September 2026 fell year on year, so a sales recovery is not yet evident at the quarterly level.

Sales rose in Q2 and Q3 2026, but not by enough to offset the year-on-year decline. The timing of revenue from the biotech segment depends on the outcome of the conditional approval review.

The next checkpoints are the MFDS review result, annual sales and operating loss in the 2026 annual report, and whether operating losses persist in the Q1 2027 quarterly report.

07

Valuation

PER
—
PBR
1.8×
ROE
-93.9%
EPS
-₩1,219
BPS
₩685
Dividend per share
₩0

PER is not calculated because the last four quarters show net losses attributable to controlling shareholders. The 2025 annual turn to profit could bring earnings-based multiples back into view, but quarterly swings are large and make earnings-based levels harder to read.

PBR sits above 1 times, meaning the market capitalization stands at a premium to the net asset value attributable to controlling shareholders at end-2025. The dividend yield is in the 0% range, and no cash dividends were recorded from 2018 to 2022.

The pace of earnings recovery and the outcome of the pipeline approval review are the variables that will move the PBR level. Over several years the company has moved from loss to profit once, while operating losses have persisted. Non-operating items and the funding structure should be reviewed alongside valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Narrowing quarterly losses

The Q3 2026 operating loss of KRW 2.8 billion narrowed from KRW 3.85 billion a year earlier and from KRW 5.13 billion in Q2 2026. Sales bottomed at KRW 9.02 billion in Q1 2026 and rose to KRW 9.9 billion in Q2 and KRW 10.2 billion in Q3, two consecutive quarters of growth. Whether the sales recovery feeds into a smaller operating loss is the checkpoint for this view.

GV1001 conditional approval filing and pipeline

GV1001, a PSP treatment, was filed for conditional domestic approval with the MFDS in January 2026. Approval could make it the first commercialized product of the biotech segment. A domestic Phase 3 trial in Alzheimer's disease is ongoing, and preparation for a PSP Phase 2b/3 trial continues. The pipeline can be read as a growth option, which is the basis of the bullish case.

Annual turn to profit in 2025

Net income attributable to controlling shareholders was KRW 11.5 billion in 2025, a turn from a KRW 14.1 billion loss in 2024, and total net income was also KRW 11.5 billion.

The operating loss of KRW 18.1 billion remained, so the notes to the 2026 annual report are the next checkpoint for whether the turn was driven by non-operating items. Q1 2026 also posted a KRW 8.77 billion profit attributable to controlling shareholders.

09

Bear factors

Persistent operating losses and accumulated net losses

Operating losses have continued for five consecutive quarters from Q3 2025 to Q3 2026. Press reports indicate cumulative net income for January to September 2026 swung to a KRW 55.6 billion net loss. A single quarterly profit has not offset the accumulated deficit.

Delayed sales recovery and cost pressure

Cumulative sales for January to September 2026 were KRW 29.1 billion, down from KRW 34.3 billion a year earlier. Q3 2026 sales of KRW 10.2 billion fell 14.9% year on year. The cost of sales ratio rose to 69.66% in 2025 from 55.36% in 2024, putting pressure on margins. Whether sales growth can offset the higher cost ratio is central to the bearish case.

Balance sheet shift and cash flow

Operating cash flow was negative at KRW -10.1 billion in 2025. The company issued unsecured private convertible bonds in August 2025. Funding capacity and the potential share impact of the convertible bonds are key variables for shareholders.

10

Risk factors

Clinical and approval risk

The timing and outcome of the GV1001 conditional approval review have not yet been set. A rejection or delay would push back the point at which the biotech segment generates revenue. Results from the Alzheimer's Phase 3 and PSP Phase 2b/3 trials are further uncertainties. Clinical-stage programs can see their schedules shift.

Funding and dilution

The company issued unsecured private convertible bonds in August 2025. Operating cash flow was negative in each year from 2022 to 2025. If losses persist, the need for additional funding could grow. Conversion of the bonds into shares would dilute existing shareholders.

Drug pricing and distribution contract structure

Prescription drugs made up 79.82% of sales at end-2025, making the company sensitive to price adjustments. The domestic industry is pursuing new drug development under drug price regulation. Eighteen prescription products depend on a partner contract, so a change in terms could affect sales directly.

11

What to watch next

  1. After November 18, 2026 (timing not yet set)

    MFDS review result for conditional approval of GV1001 for PSP. The decision will set the timing of commercialization for the biotech segment.

  2. Around mid-March 2027

    Filing of the 2026 annual report, which will confirm full-year 2026 sales, operating loss and Q4 results. The 2025 annual report was filed on March 18, 2026.

  3. Around mid-May 2027

    Q1 2027 quarterly report. Check whether the five-quarter run of operating losses ends and whether sales exceed the KRW 10.2 billion level of Q3 2026.

12

Overall view

Samsung Pharmaceutical turned to a net profit attributable to controlling shareholders of KRW 11.5 billion in 2025, but operating losses persisted for four consecutive years from 2022 to 2025.

In Q3 2026 the operating loss narrowed to KRW 2.8 billion and sales rose for two consecutive quarters, yet sales were still down 14.9% year on year. The four quarters to Q3 2026 total a net loss attributable to controlling shareholders of KRW 114.8 billion.

A higher cost of sales ratio and lower cumulative sales for January to September 2026 remain open challenges. Prescription drugs make up 79.82% of sales, and the biotech segment sits in the conditional approval review and clinical stages.

The debt-to-equity ratio rose to 38.3% at end-2025, and operating cash flow was negative in every year from 2022 to 2025. Bullish factors are the narrowing quarterly loss and the filed pipeline, while bearish factors are the accumulated net loss, cost pressure and slow sales recovery. The next checkpoints are the MFDS review result and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. butler.works
  4. comp.fnguide.com
  5. vegannews.co.kr
  6. accidentalorder.com
  7. wcomp.fnguide.com
  8. k5.co.kr
  9. markets.hankyung.com
  10. kpanews.co.kr
  11. medipharmhealth.co.kr
  12. eugenefn.com
  13. fnnews.com
  14. en.fnnews.com
  15. etoday.co.kr
  16. medicopharma.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis